A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
COLGATE PALMOLIVE CO
CL
$73.6B
Mkt Cap
$90.75
+0.74%
COLGATE PALMOLIVE CO (CL) has a current P/E ratio of 34.5, compared to its historical median P/E of 26.2. The stock is currently considered Expensive based on its historical valuation range.
COLGATE PALMOLIVE CO (CL) has a 5-year average return on invested capital (ROIC) of 36.2%. This indicates strong capital allocation and a potential competitive advantage.
COLGATE PALMOLIVE CO (CL) has a market capitalization of $72.6B. It is classified as a large-cap stock.
Yes, COLGATE PALMOLIVE CO (CL) pays a dividend with a trailing twelve-month yield of 2.53%. The company also returns capital through share buybacks, with a buyback yield of 1.70%.
Based on historical P/E analysis, COLGATE PALMOLIVE CO (CL) appears expensive. The current P/E of 34.5 is 32% above its historical median of 26.2. The estimated fair value CAGR (P/E method) is 0.3%.
COLGATE PALMOLIVE CO (CL) operates in the Perfumes, Cosmetics & Other Toilet Preparations industry, within the Consumer Defensive sector.
COLGATE PALMOLIVE CO (CL) reported annual revenue of $20.4 billion in its most recent fiscal year, based on SEC EDGAR filings.
Colgate-Palmolive is a global consumer health company operating in two segments: Oral, Personal and Home Care, and Pet Nutrition. The company is a leader in oral care with global market share in toothpaste and manual toothbrushes, selling under brands including Colgate, Darlie, elmex, hello, meridol, Sorriso and Tom's of Maine, and also holds leading positions in liquid hand soap and other personal care categories through brands such as Palmolive, Protex, Softsoap, Irish Spring, Lady Speed Stick, and Sanex. Home Care products include dishwashing liquids, household cleaners and fabric conditioners marketed under brands such as Ajax, Fabuloso, Palmolive and Suavitel. Through Hill's Pet Nutrition, the company is a leader in specialty pet nutrition for dogs and cats, with products marketed in over 80 countries under brands including Hill's Science Diet, Hill's Prescription Diet and Prime100. Oral, Personal and Home Care products accounted for 44%, 17% and 16% of net sales respectively in 2025, while Pet Nutrition represented 23% of sales. The company distributes its products through retailers, wholesalers, distributors, authorized pet supply retailers, veterinarians and eCommerce channels, with Walmart and affiliates representing approximately 11% of net sales. Products are marketed in over 200 countries and territories, with approximately two-thirds of revenues generated outside the United States and over 84% of employees located internationally. The company competes in a highly competitive omni-channel marketplace increasingly defined by digital retail, eCommerce, social commerce and direct-to-consumer channels, supported by advertising, promotion and digital marketing to build brand awareness and trial.
【Navigating volatile cost environment】 Management expects emerging markets to continue driving growth through the balance of 2026, with sequential improvement anticipated in North America as innovation reaches consumers and category trends stabilize. The company has embedded significant raw material and packaging cost inflation into guidance, with oil assumed at approximately $110 per barrel and spending in raw materials and logistics expected to be up more than 20% year-on-year, though management believes pricing actions and revenue growth management productivity can offset these headwinds while maintaining earnings per share guidance. The company announced an updated cost-reduction program targeting $200 million to $300 million in annualized savings, with the majority flowing through in 2027 and 2028, to fund investments in the 2030 strategy and drive consistent compounded dollar-based earnings per share growth. Management expects categories to remain sluggish in the near term but anticipate modest improvement as the year progresses, with flexibility built into guidance to accommodate various levels of category growth and continued consumer uncertainty.
| Metric | Target | Period |
|---|---|---|
| Organic sales growth | 1%–4% | FY2026 |
| Cost reduction program savings | $200 million–$300 million | Through end of 2028 |
| Raw materials and packaging cost inflation | $300 million additional | FY2026 |
| Raw materials and logistics spending increase | More than 20% year-on-year | FY2026 |
| Oil price assumption | Approximately $110 per barrel | FY2026 |
Organic sales growth (FY2026): “we've maintained our organic sales growth guidance in the 1%- 4%”
Cost reduction program savings (Through end of 2028): “we now expect that we'll be able to generate $200 million-$300 million of savings over the term of the program”
Raw materials and packaging cost inflation (FY2026): “the assumptions that we have embedded into our guidance for the year include the $300 million of additional raw materials”
Raw materials and logistics spending increase (FY2026): “we now expect that spending in those areas to be up more than 20% year-on-year for the full year”
Oil price assumption (FY2026): “We're assuming oil roughly at around $110”
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q4 FY2025 Earnings Call, Q3 FY2025 Earnings Call, Q2 FY2025 Earnings Call, Q1 FY2025 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 20.8B | 20.4B | 20.1B | 19.5B | 18.0B | 17.4B |
| Net Income | 2.1B | 2.1B | 2.9B | 2.3B | 1.8B | 2.2B |
| EPS | $2.59 | $2.63 | $3.51 | $2.77 | $2.13 | $2.55 |
| Free Cash Flow | 3.8B | 3.6B | 3.5B | 3.0B | 1.9B | 2.8B |
| ROIC | 29.7% | 37.0% | 45.8% | 36.6% | 27.4% | 34.1% |
| Gross Margin | 60.1% | 60.1% | 60.5% | 58.2% | 57.0% | 59.6% |
| Debt/Equity | 62.59 | 140.06 | 40.55 | 12.89 | 24.44 | 12.52 |
| Dividends/Share | $2.29 | $2.08 | $2.48 | $1.91 | $1.86 | $1.79 |
| Operating Income | 3.2B | 3.3B | 4.3B | 4.0B | 2.9B | 3.3B |
| Operating Margin | 15.4% | 16.2% | 21.2% | 20.5% | 16.1% | 19.1% |
| ROE | 1440.0% | 3948.1% | 1362.7% | 455.4% | 353.5% | 320.4% |
| Shares Outstanding | 800M | 811M | 823M | 830M | 838M | 849M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 17.3B | 16.0B | 15.2B | 15.5B | 15.5B | 15.7B | 16.5B | 17.4B | 18.0B | 19.5B | 20.1B | 20.4B | 20.8B |
| Gross Margin | 58.5% | 58.6% | 60.0% | 60.0% | 59.4% | 59.4% | 60.8% | 59.6% | 57.0% | 58.2% | 60.5% | 60.1% | 60.1% |
| R&D | 277M | 274M | 289M | 285M | 277M | 281M | 290M | 307M | 320M | 343M | 355M | 366M | 366M |
| SG&A | 6.0B | 5.5B | 5.1B | 5.4B | 5.4B | 5.6B | 6.0B | 6.4B | 6.6B | 7.2B | 7.7B | 7.9B | 8.1B |
| EBIT | 3.6B | 2.8B | 4.0B | 3.7B | 3.7B | 3.6B | 3.9B | 3.3B | 2.9B | 4.0B | 4.3B | 3.3B | 3.2B |
| Op. Margin | 20.6% | 17.4% | 26.0% | 24.0% | 23.8% | 22.6% | 23.6% | 19.1% | 16.1% | 20.5% | 21.2% | 16.2% | 15.4% |
| Net Income | 2.2B | 1.4B | 2.4B | 2.0B | 2.4B | 2.4B | 2.7B | 2.2B | 1.8B | 2.3B | 2.9B | 2.1B | 2.1B |
| Net Margin | 12.6% | 8.6% | 16.1% | 13.1% | 15.4% | 15.1% | 16.4% | 12.4% | 9.9% | 11.8% | 14.4% | 10.5% | 10.0% |
| Non-Recurring | 195M | 357M | 93M | 152M | 88M | 57M | 13M | 367M | 422M | 24M | 59M | 589M | 589M |
| Returns on Capital | |||||||||||||
| ROIC | 26.5% | 20.5% | 36.3% | 30.6% | 56.7% | 40.4% | 40.4% | 34.1% | 27.4% | 36.6% | 45.8% | 37.0% | 29.7% |
| ROE | 126.4% | 327.2% | N/A | N/A | N/A | 2023.1% | 362.7% | 320.4% | 353.5% | 455.4% | 1362.7% | 3948.1% | 1440.0% |
| ROA | 15.9% | 10.9% | 20.3% | 16.3% | 19.7% | 17.4% | 17.4% | 14.0% | 11.6% | 14.3% | 17.8% | 13.2% | 12.6% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 3.3B | 2.9B | 3.1B | 3.1B | 3.1B | 3.1B | 3.7B | 3.3B | 2.6B | 3.7B | 4.1B | 4.2B | 4.3B |
| Free Cash Flow | 2.5B | 2.3B | 2.5B | 2.5B | 2.6B | 2.8B | 3.3B | 2.8B | 1.9B | 3.0B | 3.5B | 3.6B | 3.8B |
| Owner Earnings | 2.7B | 2.4B | 2.6B | 2.5B | 2.4B | 2.5B | 3.1B | 2.6B | 1.9B | 3.1B | 3.4B | 3.4B | 3.5B |
| CapEx | 757M | 691M | 593M | 553M | 436M | 335M | 409M | 567M | 696M | 705M | 561M | 564M | 578M |
| Maint. CapEx | 442M | 449M | 443M | 475M | 511M | 519M | 539M | 556M | 545M | 567M | 605M | 630M | 638M |
| Growth CapEx | 315M | 242M | 150M | 78M | 0 | 0 | 0 | 11M | 151M | 138M | 0 | 0 | 0 |
| D&A | 442M | 449M | 443M | 475M | 511M | 519M | 539M | 556M | 545M | 567M | 605M | 630M | 638M |
| CapEx/OCF | 23.0% | 23.4% | 18.9% | 18.1% | 14.3% | 10.7% | 11.0% | 17.1% | 27.2% | 18.8% | 13.7% | 13.4% | 13.3% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 1.4B | 1.5B | 1.5B | 1.5B | 1.6B | 1.6B | 1.7B | 1.7B | 1.7B | 1.7B | 1.8B | 1.8B | 1.8B |
| Dividend Yield | 3.1% | 3.1% | 3.0% | 2.9% | 3.3% | 3.2% | 2.9% | 2.8% | 2.8% | 3.0% | 2.4% | 2.7% | 2.5% |
| Share Buybacks | 1.5B | 1.6B | 1.3B | 1.4B | 1.2B | 1.2B | 1.5B | 1.3B | 1.3B | 1.1B | 1.7B | 1.2B | 1.2B |
| Buyback Yield | 3.0% | 3.2% | 2.8% | 2.6% | 2.8% | 2.3% | 2.3% | 2.0% | 2.1% | 1.8% | 2.4% | 1.9% | 1.7% |
| Stock-Based Comp | 131M | 125M | 123M | 127M | 109M | 100M | 107M | 135M | 125M | 122M | 135M | 155M | 172M |
| Debt Repayment | 8.5B | 9.2B | 7.3B | 4.8B | 7.4B | 6.6B | 20M | 171M | 540M | 906M | 93M | 989M | 989M |
| Balance Sheet | |||||||||||||
| Net Debt | 7.7B | 7.8B | 7.8B | 7.6B | 4.9B | 7.5B | 7.4B | 6.7B | 8.6B | 6.7B | 7.3B | 6.2B | 7.7B |
| Cash & Equiv. | 1.1B | 970M | 1.3B | 1.5B | 726M | 883M | 888M | 832M | 775M | 966M | 1.1B | 1.3B | 1.4B |
| Long-Term Debt | 5.6B | 6.2B | 6.5B | 6.6B | 6.4B | 7.3B | 7.3B | 7.2B | 8.7B | 8.2B | 7.3B | 6.9B | 7.9B |
| Debt/Equity | 7.98 | -31.84 | -38.88 | -158.58 | -62.41 | 72.81 | 11.36 | 12.52 | 24.44 | 12.89 | 40.55 | 140.06 | 62.59 |
| Interest Coverage | 26.5 | 20.1 | 25.5 | 23.8 | 25.8 | 18.4 | 21.1 | 27.8 | 16.8 | 13.3 | 14.6 | 12.4 | 12.1 |
| Equity | 1.1B | -299M | -243M | -60M | -102M | 117M | 743M | 609M | 401M | 609M | 212M | 54M | 145M |
| Total Assets | 13.4B | 11.9B | 12.1B | 12.7B | 12.2B | 15.0B | 15.9B | 15.0B | 15.7B | 16.4B | 16.0B | 16.3B | 16.6B |
| Total Liabilities | 12.1B | 12.0B | 12.1B | 12.4B | 12.0B | 14.5B | 14.8B | 14.1B | 14.9B | 15.4B | 15.5B | 16.0B | 16.1B |
| Intangibles | 1.4B | 1.3B | 1.3B | 1.3B | 1.6B | 2.7B | 2.9B | 2.5B | 1.9B | 1.9B | 1.8B | 1.5B | 1.5B |
| Retained Earnings | 18.8B | 18.9B | 19.9B | 20.5B | 21.6B | 22.5B | 23.7B | 24.4B | 24.6B | 25.3B | 26.1B | 26.6B | 26.8B |
| Working Capital | 917M | 850M | 1.0B | 1.2B | 452M | 141M | -66M | 346M | 1.1B | 538M | -442M | -1.1B | 148M |
| Current Assets | 4.9B | 4.4B | 4.3B | 4.6B | 3.8B | 4.2B | 4.3B | 4.4B | 5.1B | 5.3B | 5.3B | 5.7B | 6.1B |
| Current Liabilities | 3.9B | 3.5B | 3.3B | 3.4B | 3.3B | 4.0B | 4.4B | 4.1B | 4.0B | 4.7B | 5.8B | 6.9B | 5.9B |
| Per Share Data | |||||||||||||
| EPS | 2.36 | 1.52 | 2.72 | 2.28 | 2.75 | 2.75 | 3.14 | 2.55 | 2.13 | 2.77 | 3.51 | 2.63 | 2.59 |
| Owner EPS | 2.95 | 2.61 | 2.87 | 2.76 | 2.79 | 2.92 | 3.58 | 3.10 | 2.25 | 3.68 | 4.09 | 4.21 | 4.42 |
| Book Value | 1.24 | -0.33 | -0.27 | -0.07 | -0.12 | 0.14 | 0.87 | 0.72 | 0.48 | 0.73 | 0.26 | 0.07 | 0.18 |
| Cash Flow/Share | 3.57 | 3.24 | 3.50 | 3.44 | 3.50 | 3.64 | 4.33 | 3.91 | 3.05 | 4.51 | 4.99 | 5.18 | 3.41 |
| Dividends/Share | 1.57 | 1.64 | 1.68 | 1.59 | 1.82 | 1.71 | 1.75 | 1.79 | 1.86 | 1.91 | 2.48 | 2.08 | 2.29 |
| Shares Out. | 923.7M | 910.5M | 897.4M | 887.7M | 872.7M | 860.7M | 858.3M | 849.4M | 838.0M | 830.3M | 823.1M | 810.6M | 800.2M |
| Valuation | |||||||||||||
| P/E Ratio | 23.1 | 34.6 | 19.4 | 27.1 | 18.2 | 21.7 | 24.0 | 29.9 | 34.3 | 27.2 | 25.4 | 30.1 | 35.0 |
| P/FCF | 19.8 | 21.2 | 18.6 | 21.9 | 16.7 | 18.4 | 19.6 | 23.5 | 32.9 | 20.6 | 20.7 | 17.7 | 19.3 |
| EV/EBIT | 15.3 | 18.8 | 13.3 | 15.7 | 13.2 | 16.2 | 18.2 | 21.1 | 23.6 | 17.3 | 18.7 | 21.4 | 25.1 |
| Price/Book | 44.0 | N/A | N/A | N/A | N/A | 439.2 | 87.2 | 106.5 | 152.5 | 102.6 | 345.9 | N/A | 500.8 |
| Price/Sales | 2.7 | 3.0 | 3.3 | 3.4 | 3.1 | 3.2 | 3.4 | 3.5 | 3.3 | 3.0 | 3.7 | 3.4 | 3.5 |
| FCF Yield | 5.0% | 4.7% | 5.4% | 4.6% | 6.0% | 5.4% | 5.1% | 4.3% | 3.0% | 4.9% | 4.8% | 5.7% | 5.2% |
| Market Cap | 50.3B | 47.9B | 47.3B | 54.8B | 43.8B | 51.4B | 64.8B | 64.8B | 61.1B | 62.5B | 73.3B | 64.2B | 72.6B |
| Avg. Price | 50.17 | 52.30 | 55.82 | 58.82 | 55.50 | 58.98 | 65.65 | 71.08 | 71.22 | 70.85 | 90.12 | 84.70 | 90.75 |
| Year-End Price | 54.49 | 52.57 | 52.72 | 61.74 | 50.18 | 59.70 | 75.46 | 76.33 | 72.95 | 75.24 | 89.10 | 79.24 | 90.75 |
COLGATE PALMOLIVE CO passes 6 of 9 quality checks, suggesting mixed fundamentals.
COLGATE PALMOLIVE CO trades at 34.5x trailing earnings, compared to its 15-year median P/E of 26.2x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 20.0x vs a median of 20.1x. The company's 5-year average ROIC is 36.2% with a gross margin of 59.1%. Total shareholder yield (dividends + buybacks) is 4.2%. At current prices, the estimated annualized return to fair value is +2.8%.
COLGATE PALMOLIVE CO (CL) has a net profit margin of 10.5%. This is a healthy margin.
COLGATE PALMOLIVE CO (CL) generated $3.6 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
COLGATE PALMOLIVE CO (CL) has a debt-to-equity ratio of 140.06. This indicates higher leverage, which may increase financial risk.
COLGATE PALMOLIVE CO (CL) reported earnings per share (EPS) of $2.63 in its most recent fiscal year.
COLGATE PALMOLIVE CO (CL) has a return on equity (ROE) of 3948.1%. This indicates the company generates strong returns for shareholders.
COLGATE PALMOLIVE CO (CL) has a 5-year average gross margin of 59.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for COLGATE PALMOLIVE CO (CL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
COLGATE PALMOLIVE CO (CL) has a book value per share of $0.07, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management expects emerging markets to continue driving growth through the balance of 2026, with sequential improvement anticipated in North America as innovation reaches consumers and category trends stabilize. The company has embedded significant raw material and packaging cost inflation into guidance, with oil assumed at approximately $110 per barrel and spending in raw materials and logistics expected to be up more than 20% year-on-year, though management believes pricing actions and revenue growth management productivity can offset these headwinds while maintaining earnings per share guidance. The company announced an updated cost-reduction program targeting $200 million to $300 million in annualized savings, with the majority flowing through in 2027 and 2028, to fund investments in the 2030 strategy and drive consistent compounded dollar-based earnings per share growth. Management expects categories to remain sluggish in the near term but anticipate modest improvement as the year progresses, with flexibility built into guidance to accommodate various levels of category growth and continued consumer uncertainty.
Based on recent SEC filings and earnings calls, COLGATE PALMOLIVE CO (CL) has provided the following forward guidance: Organic sales growth: 1%–4% (FY2026); Cost reduction program savings: $200 million–$300 million (Through end of 2028); Raw materials and packaging cost inflation: $300 million additional (FY2026); Raw materials and logistics spending increase: More than 20% year-on-year (FY2026); Oil price assumption: Approximately $110 per barrel (FY2026).